'BIO KOREA 2026' to Be Held Next Month... AI and Investment Strategies All in One Place

Global Pharmaceutical Companies Including AbbVie, Eli Lilly, and Amgen to Participate
Six Key Topics to Be Discussed, Including AI and Open Innovation

The BIO KOREA 2026, South Korea's premier biohealth industry convention jointly hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do, will take place at COEX in Gangnam-gu, Seoul from April 28 to 30, 2026.

The Korea Health Industry Development Institute announced on March 16 that BIO KOREA 2026 will be held under the theme "Breakthrough, Beyond the Future." The conference will consist of 12 sessions across six main topics. These topics include: ▲Artificial Intelligence (AI) & Digital Health ▲Alternative Toxicity Testing ▲Advanced Technologies ▲Open Innovation ▲Global Expansion Strategies ▲Investment Trends.

In each session, experts from various fields will participate to provide an overview of the entire lifecycle of the biohealth industry, from research and development (R&D) to investment attraction. The “Investment Trends” session, held on the opening day, will feature global venture capital (VC) firms and public and sovereign wealth funds, including the Coalition for Epidemic Preparedness Innovations (CEPI) and CBC Group, sharing insights on global investment market trends and strategic investment models.

The "Open Innovation" session will include global pharmaceutical companies such as AbbVie Global, Eli Lilly, Amgen, and AstraZeneca, who will introduce AI-based R&D strategies and examples of global collaboration. In the "Advanced Technologies" session, Ionis Pharmaceuticals, Olix, and Autotelic Bio will join to discuss RNA-based therapeutic development strategies and global research trends.

On the second day, the "AI & Digital Health" session will feature Qnova, Galux, Calysi, and Arontier, who will present AI-driven drug discovery platforms and data-based R&D strategies. In the "Investment Trends" session, domestic and international investment institutions and portfolio companies will present investment cases, seeking new investment opportunities for biohealth companies. The "Advanced Technologies" session will bring together overseas advanced regenerative medicine-related institutions and policy experts from Australia and the Nordic region, who will share strategies for building regenerative medicine industry ecosystems and international cooperation cases.

On the final day, the "Global Expansion Strategies" session will feature companies such as Fraser Therapeutics and Thermo Fisher Scientific, who will present various global expansion cases and commercialization strategies for Korean biohealth companies, including technology transfer, joint R&D, and global manufacturing partnerships. In the "Alternative Toxicity Testing" session, the discussion will focus on non-animal testing-based new drug development strategies, centering on next-generation nonclinical evaluation technologies such as organoids, organ-on-a-chip, and AI-based toxicity prediction models, as well as global regulatory trends.

Business partnering will also take place throughout the event. Key participating companies announced so far include Chong Kun Dang, SK Pharmteco, Boehringer Ingelheim, Prestige Biopharma, Takeda Pharmaceutical, Amgen, and ST Pharm. A "Partnering Reception" will be held for business partnering participants, providing further networking opportunities.

This content was produced with the assistance of AI translation services.